메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Deep Dutta (Center For Endocrinology Diabetes Arthritis & Rheumatism (CEDAR) Superspeciality Healthcare) Ritin Mohindra (Postgraduate Institute of Medical Education and Research) Kunal Mahajan (Holy Heart Advanced Cardiac Care Center) Meha Sharma (CEDAR Superspeciality Healthcare)
저널정보
대한당뇨병학회 Diabetes and Metabolism Journal Diabetes and Metabolism Journal Vol.47 No.1
발행연도
2023.1
수록면
72 - 81 (10page)
DOI
10.4093/dmj.2022.0035

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background: No meta-analysis has analysed efficacy and safety of fast-acting aspart insulin (FIAsp) with insulin pump in type 1 diabetes mellitus (T1DM).Methods: Electronic databases were searched for randomised controlled trials (RCTs) involving T1DM patients on insulin pump receiving FIAsp in intervention arm, and placebo/active comparator insulin in control arm. Primary outcome was to evaluate changes in 1- and 2-hour post-prandial glucose (1hPPG and 2hPPG). Secondary outcomes were to evaluate alterations in percentage time with blood glucose <3.9 mmol/L (hypoglycaemia), time in range (TIR) blood glucose 3.9 to 10 mmol/L, insulin requirements and adverse events.Results: Data from four RCTs involving 640 patients was analysed. FIAsp use in insulin pump was associated with significantly greater lowering of 1hPPG (mean difference [MD], –1.35 mmol/L; 95% confidence interval [CI], –1.72 to –0.98; <i>P</i><0.01; I<sup>2</sup>=63%) and 2hPPG (MD, –1.19 mmol/L; 95% CI, –1.38 to –1.00; <i>P</i><0.01; I<sup>2</sup>=0%) as compared to controls. TIR was comparable among groups (MD, 1.06%; 95% CI, –3.84 to 5.96; <i>P</i>=0.67; I<sup>2</sup>=70%). Duration of blood glucose <3.9 mmol/L was lower in FIAsp group, approaching significance (MD, –0.91%; 95% CI, –1.84 to 0.03; <i>P</i>=0.06; I<sup>2</sup>=0%). Total hypoglycaemic episodes (risk ratio [RR], 1.35; 95% CI, 0.55 to 3.31; <i>P</i>=0.51; I<sup>2</sup>=0%), severe hypoglycaemia (RR, 2.26; 95% CI, 0.77 to 6.66; <i>P</i>=0.14), infusion site reactions (RR, 1.35; 95% CI, 0.63 to 2.93; <i>P</i>=0.77; I<sup>2</sup>=0%), and treatment-emergent adverse events (RR, 1.13; 95% CI, 0.80 to 1.60; <i>P</i>=0.50; I<sup>2</sup>=0%) were comparable.Conclusion: FIAsp use in insulin pump is associated with better post-prandial glycaemic control with no increased hypoglycaemia or glycaemic variability.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0